Search results
Eli Lilly (LLY) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 7 days agoRevenue in the rest of the world increased 31% in constant currency, primarily driven by volume growth from Mounjaro and to a lesser extent, Verzenio and...
Eli Lilly's Weight-Loss Drug Still Going Strong, Boosts Annual Forecast
Benzinga via AOL· 7 days agoThe volume increase was primarily driven by growth from Mounjaro, Zepbound, Verzenio, and Jardiance,...
Eli Lilly (LLY) Q1 Earnings Top, Sales Miss, 2024 View Raised
Zacks via Yahoo Finance· 7 days agoEli Lilly (LLY) beats first-quarter estimates for earnings but misses the same for sales. It raises...
Eli Lilly and Company (NYSE:LLY) Trading 2.6% Higher After Strong Earnings
ETF DAILY NEWS· 9 hours agoEli Lilly and Company (NYSE:LLY – Get Free Report) shares rose 2.6% during trading on Monday following a stronger than expected earnings report. Eli Lilly and Company had a return on equity ...
Is Eli Lilly Stock A Buy After Weight-Loss Drug Crushes Quarterly Sales Forecasts?
Investor's Business Daily· 7 days agoTrulicity, another diabetes treatment, had $1.46 billion in first-quarter sales, down 26% and below...
Decoding Eli Lilly and Co (LLY): A Strategic SWOT Insight
GuruFocus.com via Yahoo Finance· 6 days agoThe financial overview indicates that LLY has experienced revenue growth driven by increased volume...
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims - Comfort...
Benzinga· 4 days agoThe first-quarter 2024 earnings season is almost over as far as large drugmakers are concerned. Eli...
ETFs to Buy as Eli Lilly Beats Q1 Earnings, Lifts Outlook
Zacks via Yahoo Finance· 6 days agoEli Lilly and Company (LLY) raised its outlook for 2024 on rapidly climbing sales of the new obesity...
These 3 Companies Recently Lifted Guidance
Zacks via Yahoo Finance· 7 days agoRevenue throughout the period grew 26% year-over-year, driven by strong demand within Mounjaro, Zepbound, Verzenio, and Jardiance. The results impressed...
IBD Stock Of The Day Eli Lilly Surges After Weight-Loss Drug Obliterates Sales Views
Investor's Business Daily· 7 days agoHe kept his in-line (neutral) rating on Eli Lilly stock. Sales of other key products, cancer drug...